Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 31Recurrence 4Smoldering Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 8dinutuximab 7Magnetic Resonance Spectroscopy 7Topotecan 6Doxorubicin 6sargramostim 5Vincristine 5Stem Cell Transplantation 5Radiation 5Platinum 5Melphalan 5Isotretinoin 5Colony-Stimulating Factors 5Cisplatin 5Biopsy 51,2-diaminocyclohexaneplatinum II citrate 5Temozolomide 4Specimen Handling 4Irinotecan 4Etoposide 4Congresses as Topic 4Carboplatin 4Thiotepa 3Busulfan 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2temsirolimus 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ganglioneuroblastoma × iberdomide × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡